Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.

MLA

Mengqiu Wu, et al. “Anti-Anemia Drug FG4592 Retards the AKI-to-CKD Transition by Improving Vascular Regeneration and Antioxidative Capability.” Clinical Science, vol. 135, no. 14, July 2021, pp. 1707–26. EBSCOhost, https://doi.org/10.1042/CS20210100.

APA

Mengqiu Wu, Weiyi Chen, Mengqiu Miao, Qianqian Jin, Shengnan Zhang, Mi Bai, Jiaojiao Fan, Yue Zhang, Zhanjun Jia, & Songming Huang. (2021). Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability. Clinical Science, 135(14), 1707–1726. https://doi.org/10.1042/CS20210100

Chicago

Mengqiu Wu, Weiyi Chen, Mengqiu Miao, Qianqian Jin, Shengnan Zhang, Mi Bai, Jiaojiao Fan, Yue Zhang, Zhanjun Jia, and Songming Huang. 2021. “Anti-Anemia Drug FG4592 Retards the AKI-to-CKD Transition by Improving Vascular Regeneration and Antioxidative Capability.” Clinical Science 135 (14): 1707–26. doi:10.1042/CS20210100.